[UniverCité] Aspivix lance sa phase II au CHUV

Today, ASPIVIX is proud to announce the start of its Phase II First-in-Women trial at the CHUV | Lausanne university hospital and HUG – Hôpitaux in Switzerland.

The ADVANCE Women* is a two-arms, randomized trial that will enroll between 80 and 120 women undergoing insertion of an Intrauterine Contraceptive Device #IUD.

Investigators will compare the investigational CAREVIX™ device from Aspivix versus the standard of care cervical #Tenaculum, to evaluate Patient-reported pain scores (VAS) at specific time points during the IUD insertion procedure.

Results of Phase I first-in-women trial can be found here https://prn.to/3xkHLud

MORE